Slide 1: 4D and Half Year Management Presentation – 25th February, 2021
For personal use only 4D and Half Year Management Presentation – 25th February, 2021 4D and Half Year Management Presentation – 25th February, 2021 1
Slide 2: Important notice
Important notice For personal use only This presentation has been prepared by Control Bionics Ltd (ACN 115 465 462) (‘Control Bionics’ or the ‘Company’). It contains general information about the Company and its subsidiaries and business, current as at the date of the presentation. It has been prepa
Slide 3: Disclaimer
Disclaimer For personal use only Disclaimer To the maximum extent permitted by law, the Company (including its subsidiaries) and their respective directors, officers, employees, contractors, agents and advisers (together the ‘Relevant Persons’): • Disclaims any obligations or undertaking to release
Slide 4: Presenters
Presenters For personal use only Rob Wong John Bell Neale Java CEO Chief Financial Officer Chief Financial Officer (Incoming March 1, 2021) 4D and Half Year Management Presentation – 25th February, 2021 4
Slide 5: Agenda
Agenda For personal use only 11am-11.30am • Company Overview ‒ Mission ‒ Products & Technology ‒ Market Overview ‒ Growth Strategy • Half Year Highlights • Financial Performance • Growth Initiatives & Progress • Q&A via webinar chat 4D and Half Year Management Presentation – 25th February, 2021 5
Slide 6: Company Overview
For personal use only Company Overview 4D and Half Year Management Presentation – 25th February, 2021 6
Slide 7: Company Mission
Company Mission For personal use only Control Bionics’ aim is to become the world’s leading provider of innovative augmentative communications and control devices for people with speech and movement disabilities 4D and Half Year Management Presentation – 25th February, 2021 7
Slide 8: Technology and Products
Technology and Products For personal use only Technology : NeuroNode NeuroNode 3 (iOS) NeuroNode Trilogy & Trilogy GridPad Patented NeuroNode NeuroNode 3.0 NeuroNode Trilogy - “Faster Technology “Communicate with Speed, Less Fatigue, More confidence” Control” Power of 3 Average Revenue Per System $2
Slide 9: Market Overview
Market Overview For personal use only Customers Channel to Market Regulatory Environment End users: • Speech Language Clinicians • Rehabiltation Centres • FDA approved • ALS / MND USA • Accredited Medicare/Medicaid • Spinal Cord Injuries • Multiple Sclerosis Government & Private Funding • TGA regist
Slide 10: Growth Strategy – Geographic Expansion
Growth Strategy – Geographic Expansion For personal use only Australian Expansion USA Expansion Japan Market Entry • Sales & marketing and corporate • Sales, marketing, operations infrastructure for product • Sales, marketing & channel development into the infrastructure investment development & man
Slide 11: Half Year FY 2021 Highlights
For personal use only Half Year FY 2021 Highlights 4D and Half Year Management Presentation – 25th February, 2021 11
Slide 12: Highlights Half Year FY21
Highlights Half Year FY21 For personal use only • Successful IPO in December 2020 raising $15m created a strong balance sheet to fund global growth • Solid Half Year performance with revenue up 22% at $2m and unit sales up 25%, despite significant COVID-19 impact, particularly in the USA • Modest lo
Slide 13: Revenue & Units Snapshot
Revenue & Units Snapshot For personal use only Revenue Share by Market for the Half Year as at Dec 2019 Revenue for the Half Year 2019 v 2020 AUD $2,500,000 22% Australia, • Revenue $2m up by 22% 23% $2,000,000 $2,005,390 over PCP $1,642,213 $1,500,000 • Unit sales increased by 25% $1,000,000 • USA
Slide 14: Profit and Loss for the Half Year ended December 31st 2020
Profit and Loss For the Half Year ended December 31st 2020 P&L Half Year Half Year For personal use only Dec 31st 2020 Dec 31st 2019 $000 $000 • Revenue • 22% increase YOY for the half year Revenue 2,005 1,642 • Australia up by 84% and US up by 3% (despite COVID-19 impact) • Grants and other income
Slide 15: Cash Flow Statement for the Half Year Ended December 2020
Cash Flow Statement FOR THE HALF YEAR ENDED 31 DECEMBER 2020 For personal use only Cash Flow For the Half Year For the Half Year Ended 31 Dec. Ended 31 Dec 2020 2019 $000 $000 Cash flow used in operating activities (1,602) (644) • IPO proceeds • COVID support and R&D rebate Cash used in investing ac
Slide 16: Balance Sheet
Balance Sheet For personal use only Summary balance 31 Dec 2020 June 30 2020 sheet $000 $000 • Strong Balance Sheet to execute growth strategy as described in the Prospectus Current Assets 15,931 1,924 even with current COVID-19 risks • Zero debt Other Assets 4,490 4,421 Total Assets 20,421 6,345 To
Slide 17: Update by Region
Update by Region For personal use only USA • First quarter revenue impacted by COVID-19, but also reduced cost exposure in marketing and travel. • Some recovery in late Q2 with funding seasonality and growing awareness of Trilogy and Trilogy GridPad (Soft launched September 2020). Access to faciliti
Slide 18: Senior Management Changes
Senior Management Changes For personal use only • Jamie Lemsing appointed as International Market Development Manager February 2021 • Experienced ASX CFO, John Bell appointed on part time basis October 2020 • Brett Crowley appointed as Company Secretary October 2020 • Neale Java joined as full-time
Slide 19: COVID-19 Update Half-Year FY
COVID-19 Update Half-Year FY 21 For personal use only • COVID-19 impacted ability to reach specifying clinicians and our immune compromised clients globally • In Q2 there was some easing of sales staff access in the USA, but correspondingly a tightening of conditions in Australia. COVID-19 stalled i
Slide 20: Outlook
For personal use only Outlook 4D and Half Year Management Presentation – 25th February, 2021 20
Slide 21: Outlook
Outlook • Cautiously optimistic about sales in the next two For personal use only quarters and especially beyond, but COVID-19 uncertainty can delay conversion and our ability to build pipeline • Core interest in our NeuroNode systems is building with our users and clinicians are becoming more aware
Slide 22: Q & A via webinar platform
For personal use only Q & A via webinar platform 4D and Half Year Management Presentation – 25th February, 2021 22
Slide 23: Life-Changing Connections
Life-Changing Connections For personal use only 4D and Half Year Management Presentation – 25th February, 2021 23
Slide 24: Contact details
For personal use only AUSTRALIA +61 3 9897 3576 Suite G.03 171 Union Road Surrey Hills VIC 3127 USA 745 Center Street, Suite 303 Milford OH 45150 USA Contacts: Investors Brett Crowley Company Secretary brettcrowley@controlbionics.com Media Relations Ben Henri MC Partners Ben.henri@mcpartners.com.au